



IN THE CLAIMS:

Please cancel claims 1-8 and 12-16, add new claims 17-38 as shown below. A clean copy of the pending claims, after amendments, is attached as Appendix A.

MARKED-UP COPY:

Underlining indicates insertions
[brackets indicate deletions]

1. (Canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
12. (Canceled)
13. (Canceled)
14. (Canceled)
15. (Canceled)
16. (Canceled)
17. (New) A product containing an alkylating anthracycline of formula Ia or Ib:



and an antimetabolite compound as a combined preparation that has a synergistic antineoplastic effect for simultaneous, separate or sequential use in treatment of tumors in mammals.

18. (New) The product according to claim 17, further containing a pharmaceutically acceptable carrier or excipient.

19. (New) The product according to claim 17 or claim 18, wherein the mammal is a human.

20. (New) The product according to claim 17 or claim 18 wherein the alkylating anthracycline is a 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methanesulfonyl daunorubicin.

21. (New) A product according to claim 17 or claim 18 wherein the antimetabolite compound is a cytidine analog.

22. (New) A product according to claim 17 or claim 18 wherein the antimetabolite compound is a 5-fluoropyrimidine.

23. (New) A product according to claim 21 wherein the cytidine analog is gemcitabine.

24. (New) A product according to claim 22 wherein the 5-fluoropyrimidine is 5-fluorouricil.

25. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and, as an active ingredient, an alkylating anthracycline of formula Ia or

Ib as defined in claim 17 and an antimetabolite compound that has a synergistic antineoplastic effect in mammals when administered simultaneously, separately or sequentially.

26. (New) A pharmaceutical composition according to claim 25 wherein the mammal is a human.

27 (New) A pharmaceutical composition according to claim 25 or claim 26 wherein the antimetabolite compound is 5-fluorouricil or gemcitabine.

28. (New) A method for treating tumors in a mammal in need thereof, comprising administering the alkylating anthracycline of formula Ia or Ib and an antimetabolite compound as claimed in claim 17 or claim 18 to said mammal in a synergistic antineoplastic effective amount.

29. (New) The method according to claim 28 wherein the mammal is a human.

30. (New) The method according to claim 28 or claim 29 wherein the antimetabolite compound is 5-fluorouricil or gemcitabine.

31. (New) The method according to claim 28 or claim 29 wherein a synergistic antineoplastic effective amount of the alkylating anthracycline of formula Ia or Ib and the antimetabolite compound I are administered simultaneously, separately or sequentially.

32. (New) A method for treatment of metastasis in a mammal in need thereof, comprising administering the alkylating anthracycline of formula Ia or Ib and an antimetabolite compound as claimed in claim 17 or claim 18 to said mammal in a synergistic antineoplastic effective amount.

- B2
Cond*
33. (New) The method according to claim 32 wherein the mammal is a human.
34. (New) The method according to claim 32 or claim 33 wherein the antimetabolite compound is 5-fluorouricil or gemcitabine.
35. (New) The method according to claim 32 or claim 33 wherein a synergistic antineoplastic effective amount of the alkylating anthracycline of formula Ia or Ib and the antimetabolite compound I are administered simultaneously, separately or sequentially.
36. (New) A method for treating a tumor by the inhibition of angiogenesis in a mammal in need thereof, comprising administering the alkylating anthracycline of formula Ia or Ib and an antimetabolite compound as claimed in claim 17 or claim 18 to said mammal in a synergistic antineoplastic effective amount.
37. (New) The method according to claim 36 wherein the mammal is a human.
38. (New) The method according to claim 36 or claim 37 wherein the antimetabolite compound is 5-fluorouricil or gemcitabine.
39. (New) The method according to claim 36 or claim 37 wherein a synergistic antineoplastic effective amount of the alkylating anthracycline of formula Ia or Ib and the antimetabolite compound I are administered simultaneously, separately or sequentially.